Literature DB >> 8517689

Nonparametric approach to population pharmacokinetics in oncology patients receiving aminoglycoside therapy.

J F Inciardi1, K K Batra.   

Abstract

A nonparametric expectation maximization approach to the study of population pharmacokinetics is described for an aminoglycoside antibiotic. The method is used to explore population estimates for gentamicin clearance (liters per hour per creatinine clearance) and volume of distribution (liters per kilogram) in tumor patients. Joint and marginal probability distributions are plotted and further characterized by using standard descriptors such as mean, median, mode, standard deviation, skewness, and kurtosis. Results of additional analyses using hematologic or solid tumor subpopulations agree with those of a recent larger study which found no significant pharmacokinetic differences between these groups. Nonparametric maximum-expectation analyses are convenient and allow exploratory analysis of population estimates directly from routine laboratory information.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8517689      PMCID: PMC187886          DOI: 10.1128/AAC.37.5.1025

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

Review 1.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies.

Authors:  T H Grasela; E J Antal; R J Townsend; R B Smith
Journal:  Clin Pharmacol Ther       Date:  1986-06       Impact factor: 6.875

3.  Population pharmacokinetics of gentamicin. Use of the nonparametric expectation maximisation (NPEM) algorithm.

Authors:  D F Kisor; S M Watling; B J Zarowitz; R W Jelliffe
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

Review 4.  Population pharmacokinetics. Theory and clinical application.

Authors:  B Whiting; A W Kelman; J Grevel
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

5.  Gentamicin pharmacokinetics in patients with malignancies.

Authors:  J S Bertino; L A Booker; P Franck; B Rybicki
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

6.  Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method.

Authors:  W F Dodge; R W Jelliffe; C J Richardson; R A McCleery; J A Hokanson; W R Snodgrass
Journal:  Clin Pharmacol Ther       Date:  1991-07       Impact factor: 6.875

7.  Interlot variability in gentamicin and tobramycin concentration and its possible significance.

Authors:  M C Nahata; T F Hipple; M Clotz
Journal:  Ther Drug Monit       Date:  1986       Impact factor: 3.681

  7 in total
  6 in total

1.  Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa.

Authors:  G L Drusano; Robert A Bonomo; Nadzeya Bahniuk; Juergen B Bulitta; Brian Vanscoy; Holland Defiglio; Steven Fikes; David Brown; Sarah M Drawz; Robert Kulawy; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

2.  Relationship between pharmacokinetic parameters of gentamicin and patient characteristics and/or clinical data in patients with solid organ tumours.

Authors:  A Ortega; A Aldaz; J Giráldez; A Brugarolas
Journal:  Pharm World Sci       Date:  1999-10

3.  Optimization of aminoglycoside therapy.

Authors:  G L Drusano; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

4.  Population pharmacokinetics of gentamicin in patients with cancer.

Authors:  M C Rosario; A H Thomson; D I Jodrell; C A Sharp; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

5.  Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance across Body Size.

Authors:  Ryan L Crass; Brian E Ross; Brian A Derstine; Matt Lichty; June A Sullivan; Grace L Su; Stewart C Wang; Manjunath P Pai
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

6.  Ultra-High-Precision, in-vivo Pharmacokinetic Measurements Highlight the Need for and a Route Toward More Highly Personalized Medicine.

Authors:  Philip A Vieira; Christina B Shin; Netzahualcóyotl Arroyo-Currás; Gabriel Ortega; Weiwei Li; Arturo A Keller; Kevin W Plaxco; Tod E Kippin
Journal:  Front Mol Biosci       Date:  2019-08-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.